Flagship Pioneering related stories
All articles and analysis
Dr. Shelley Chu joins AbingworthAbingworth said Monday that Shelley Chu MD, PhD has joined Abingworth as a Partner. Chu was previously with Gilead Sciences where she led Business Development in Oncology, Immunotherapy and Hepatitis B, as well as R&D Strategy.
Market turbulence or not, North American investors plow into farm-tech: ReutersNorth American investors are pouring money into agriculture technology despite turbulent financial and commodity markets, as cutting-edge advances that enhance farm production bring opportunities for profits, Reuters reported. Investment in this technology is on pace in 2015 to smash last year's record US$2.36 billion, according to AgFunder, which matches startups with investors.
- Krognes named CFO of Denali Therapeutics
Steve Krognes is joining Denali Therapeutics Inc. as CFO effective Oct. 1. Krognes joins Denali from Genentech, where he has served as CFO and as a member of the Genentech Executive Committee since 2009. San Francisco-based Denali is a biotechnology company focused on developing therapies for neurodegenerative diseases. Investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund.
- Selecta Biosciences raises $38 mln
Selecta Biosciences Inc. said Tuesday it raised $38 million in a Series E financing round. OrbiMed is the largest investor in the round which includes new investors, Sanofi-Genzyme BioVentures, Ridgeback Capital Management, Osage University Partners, AJU IB Investment and Sphera Global Health Care Fund. All of Selecta’s existing investors also participated. Watertown, Massachusetts-based Selecta is clinical stage biotechnology company.
- Editas Medicine raises $120 mln
Editas Medicine said Monday it raised $120 million led by Boris Nikolic, M.D., managing director of bng0, a U.S.-based investment company that was formed to invest exclusively in Editas Medicine and includes a select group of large family offices. Other new investors include Deerfield Management, Viking Global Investors, Fidelity Management & Research Company, funds and accounts managed by T. Rowe Price Associates Inc., Google Ventures, Jennison Associates on behalf of certain clients, Khosla Ventures, EcoR1 Capital, Casdin Capital, Omega Funds, Cowen Private Investments and Alexandria Venture Investments. Cambridge, Massachusetts-based Editas is a genome editing company.
- IPO Profile: Seres Therapeutics Inc
The company, which focuses on debilitating infection of the colon, raised a $133.7 million IPO
IPO Aftermarket: Fitbit surge dominates headlines, as biotech companies continue to roll outThrough the end of June, 42 VC-backed companies have gone public on the NYSE or Nasdaq exchanges
- Pronutria Biosciences pulls in $39 mln Series C
Cambridge, Massachusetts-based Pronutria Biosiences, a developer of treatments to mediate amino acid biology, has closed $39 million in Series C funding. Fidelity Management & Research Company led the round with participation from other investors that included Flagship Ventures.
Dashboard: Fundraising down in MarchDeals, M&A and IPOs all take steps forward in the month
- VC-backed Blend Therapeutics appoints Fromkin as president and CEO
Watertown, Massachusetts-based Blend Therapeutics Inc, a biopharmaceutical company focused on treating patients with solid tumor cancers, has named Drew Fromkin as president, CEO and a member of the company’s board of directors. Previously, Fromkin worked at Clinical Data Inc where he served as President and CEO. Blend Therapeutics' backers include Eminent Venture Capital, Flagship Ventures, NanoDimension and New Enterprise Associates.